Uncovering gaps in personalised lung cancer care in Germany: a white spot analysis
Significant disparities in access to quality-assured molecular diagnostics persist. Expanding nNGM and integrating high-volume hospitals could raise coverage to over 85%. Standardising molecular diagnostics and quality requirements across nNGM, DKG, and ASV could further optimise access to high-quality personalised lung cancer care in Germany and build a unified real-world evidence base for equitable, consistent care.
Authors
- Florian Kron (ORCID: https://orcid.org/0000-0003-4907-7490)
- J. D. Roder (ORCID: https://orcid.org/0009-0009-7098-6753)
- L. Moos
- Martin Utzig (ORCID: https://orcid.org/0009-0003-1403-8827)
- Hans Christian Reinhardt (ORCID: https://orcid.org/0000-0001-5706-9349)
- Thomas Illmer
- Robert Dengler (ORCID: https://orcid.org/0000-0002-8801-9499)
- Anna Kron (ORCID: https://orcid.org/0000-0002-3047-6486)
- Scarlett Berressem
- Jürgen Wolf
- M. Brodersen (ORCID: https://orcid.org/0009-0009-5188-9552)
- Laura Harzheim
- Nils Dreiack
Institutions
- TH Köln - University of Applied Sciences (DE)
- University of Cologne (DE)
- Integrated Oncology (United States) (US)
- German Cancer Society (DE)
- Essen University Hospital (DE)
- Association of Clinical Pathologists (GB)
- QUIRIS Healthcare (DE)
- Federal Medical Centre (NG)
- University Hospital Cologne (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1186/s12885-025-15411-2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00